Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

342 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of A(H1N1) inactivated influenza virus vaccine in subjects with Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus, and to compare safety and immunogenicity data with a contemporaneously enrolled control group of age-comparable, healthy subjects.

Because certain individuals may be hypo-responsive to influenza vaccination, additional studies with high-risk groups are warranted in order to determine the optimal vaccine formulation and dosing schedule for prevention of novel H1N1 virus infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

NCT01344057

Seasonal Influenza

COMPLETED PHASE2

Study of Immune Responses to Influenza Vaccination

NCT03346772

Influenza Vaccination

RECRUITING PHASE4

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

NCT03020498

Influenza

COMPLETED PHASE4

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

NCT01342796

Seasonal Influenza Influenza Influenza Due to Unspecified Influenza Virus +1 more

COMPLETED PHASE2

Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses

NCT06824779

Volunteers Flu Vaccine

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

H1N1 Influenza Virus Chronic Pulmonary Disease Chronic Heart Disease Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Disease Subjects Receiving Vaccine with Adjuvant

Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.

Group Type EXPERIMENTAL

Focetria®

Intervention Type BIOLOGICAL

7.5 ug of HA antigen; adjuvanted; monovalent

Fluad®

Intervention Type BIOLOGICAL

15 ug of HA antigen; adjuvanted; trivalent

Chronic Disease Subjects Receiving Vaccine without Adjuvant

Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.

Group Type EXPERIMENTAL

Begrivac®

Intervention Type BIOLOGICAL

15 ug of antigen; non-adjuvanted; trivalent

Healthy Subjects Receiving Vaccine with Adjuvant

Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.

Group Type EXPERIMENTAL

Focetria®

Intervention Type BIOLOGICAL

7.5 ug of HA antigen; adjuvanted; monovalent

Fluad®

Intervention Type BIOLOGICAL

15 ug of HA antigen; adjuvanted; trivalent

Healthy Subjects Receiving Vaccine without Adjuvant

Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.

Group Type EXPERIMENTAL

Begrivac®

Intervention Type BIOLOGICAL

15 ug of antigen; non-adjuvanted; trivalent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Focetria®

7.5 ug of HA antigen; adjuvanted; monovalent

Intervention Type BIOLOGICAL

Fluad®

15 ug of HA antigen; adjuvanted; trivalent

Intervention Type BIOLOGICAL

Begrivac®

15 ug of antigen; non-adjuvanted; trivalent

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For Subjects with Chronic Diseases:

* Subjects between 18 and 70 years of age (inclusive)
* Any sex or ethnicity
* Outpatient or hospitalized subjects
* Confirmed diagnosis of chronic pulmonary and/or cardiac, and/or diabetes mellitus based on the investigator's assessment (subjects may present one or more of such conditions)
* Childbearing potential women must be willing to use an acceptable contraceptive method. Acceptable contraceptive methods are defined as one or more of the following:

1. Hormone contraceptive (such as oral, injectable, transdermal patch, subcutaneous implant, cervical ring)
2. Barrier (condom with spermicide or diaphragm with spermicide) at each intercourse and during the whole intercourse
3. Intra-uterine device (IUD)
4. Monogamous relation with vasectomized partner (must have been vasectomized at least six months before the volunteer entered the study)
* Subjects capable of following all the study procedures and available for all visits scheduled to the investigation site
* Subjects capable of understanding the nature and risk of the study proposed and sign the consent form
* The study subjects may have other underlying chronic diseases that do not involve immunosuppression (e.g. osteoarticular diseases, stable, non-progressive, non-severe neurologic disorders without cognitive impairment, ophthalmologic diseases, hypothyroidism, etc.), but their symptoms/signs must be under control through medical follow-ups and drug therapy

For Healthy Subjects:

* Subjects between 18 and 70 years of age (inclusive)
* Any sex and ethnicity
* Subjects with good health as determined by medical history, physical evaluation, and investigator's clinical opinion
* Childbearing potential women must be willing to use an acceptable contraceptive method. Acceptable contraceptive methods are defined as one or more of the following:

1. Hormone contraceptive (such as oral, injectable, transdermal patch, subcutaneous implant, cervical ring)
2. Barrier (condom with spermicide or diaphragm with spermicide) at each intercourse and during the whole sexual intercourse
3. Intra-uterine device (IUD)
4. Monogamous relation with vasectomized partner (must have been vasectomized for at least six months before the volunteer entered the study)
* Subjects capable of respecting all the study procedures and available for all the visits scheduled at the investigation site
* Subjects capable of understanding the nature and risk of the study proposed and sign the consent form

Exclusion Criteria

For Subjects with Chronic Diseases

* Previous laboratory confirmed diagnosis of an infection by the novel H1N1 virus
* Administration of other vaccine against the novel H1N1 virus within 3 months prior to inclusion in the study
* Any recent vaccine given within the last 21 days (inclusive)
* History of allergic reaction to an influenza vaccine in the past, or a current or previous occurrence of allergy to egg or egg protein, kanamycin, and neomycin sulfate
* Acute febrile disease (vaccination may be delayed up to 3 days after the resolution of the symptoms)
* History of cancer, except for skin cancer, including Kaposi's Sarcoma, basal cell carcinoma, and non-invasive malignancy related to HPV
* History of chronic hepatic or renal disease
* History of cognitive disorders
* History of progressive or severe neurological disorders, including Guillain-Barré Syndrome
* Pregnancy or breast-feeding
* Use of immunomodulatory therapy, including cyclosporin,interleukins, and interferons, within 3 months prior to inclusion in the study
* Receipt of parenteral immunoglobulin, hemotherapy, and/or plasma derivatives within 3 months prior to inclusion in the study
* Life expectancy of at least 12 months
* Receipt of any investigational product within 12 months prior to inclusion in the study

For Healthy Subjects:

* Previous laboratory confirmed diagnosis of an infection by the new virus H1N1
* Receipt of another vaccine against the new virus H1N1 within 3 months prior to inclusion in the study
* Any recent vaccine given within the last 21 days (inclusive)
* History of allergic reaction to influenza vaccine in the past, or a current or previous allergy to egg or egg protein, kanamycin, and neomycin sulfate
* Acute febrile disease (the vaccination may be delayed up to 3 days after symptoms resolution)
* Pregnancy or breast-feeding
* Receipt of parenteral immunoglobulin, hemotherapy, and/or plasma derivatives within 3 months prior to inclusion in the study
* Receipt of any investigational product within 12 months prior to inclusion in the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes